Oligodendroglioma Clinical Trial
— PRO-GLIOOfficial title:
PRO-GLIO: PROton Versus Photon Therapy in IDH-mutated Diffuse Grade II and III GLIOmas
Proton therapy is a powerful tool enabling oncologists to spare normal tissue around the target for irradiation much better than what can be achieved with photon irradiation. The infiltrative nature of IDH-mutated grade II and III diffuse glioma, however, renders proton therapy a potential problem. A randomized controlled trial (RCT) is the only option when trying to ensure that chances of long-term survival are not impaired seeking to reduce unwanted late treatment effects. Non-inferiority of proton therapy compared to photon irradiation is the primary endpoint of the RCT. Hence, PRO-GLIO has two main objectives. First, PRO-GLIO will evaluate if proton therapy is safe in patients with IDH-mutated grade II and III diffuse glioma, showing that survival figures at 2 years from radiotherapy are not poorer in the proton arm than in the photon arm. Second, we want to find the true number of patients in need of rehabilitation in both arms, and evaluate if proton therapy conveys a higher QoL than photon irradiation at 2 years from radiotherapy.
Status | Recruiting |
Enrollment | 225 |
Est. completion date | December 31, 2041 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Patients must be 18 to 65 years old at the day of consenting 2. IDH-mutated astrocytoma grade II or III, or oligodendroglioma grade II or III according to WHO 2016 3. Indication for radiotherapy 4. WHO/ECOG performance status 0-2 5. Ability to undergo MRI 6. No significant contrast enhancing tumor at the time of randomization. In recurrence patients, no contrast enhancement is allowed unless a new biopsy confirms the diagnosis of IDH-mutated astrocytoma grade 2 or 3, or oligodendroglioma grade 2 or 3. 7. Ability and willingness to travel to The Skandion Clinic for proton therapy if randomized to the proton therapy arm 8. Women of child-bearing potential (WOCBP) must agree to use an effective method of contraception during radiotherapy, chemotherapy and 1 year after completion of chemotherapy. Pregnancy is not an ineligibility criterium if radiotherapy is indicated and cannot be postponed 9. Ability to understand the information about the study and included treatment and give a written informed consent 10. Signed informed consent 11. Ability to speak and understand Norwegian or Swedish language Exclusion Criteria: 1. Prior treatment (except surgery) for diffuse glioma 2. Concomitant or previous malignancies. Exceptions are adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or in situ carcinoma of the cervix uteri with a follow-up time of at least 3 years, or other previous malignancy with a disease-free interval of at least 5 years 3. More than 2 months from randomization to start radiotherapy 4. Known CDKN2A/B homozygous deletion 5. Presence of any medical, psychological, familial, sociological, or geographical characteristic that might impair patient compliance for study protocol procedures including follow-up 6. Body weight > 150 kg |
Country | Name | City | State |
---|---|---|---|
Norway | Oslo University Hospital | Oslo |
Lead Sponsor | Collaborator |
---|---|
Oslo University Hospital | Haukeland University Hospital, Karolinska University Hospital, Lund University Hospital, Ôrebro University Hospital, Sahlgrenska University Hospital, Sweden, St. Olavs Hospital, The Skandion Clinic, University Hospital of North Norway, University Hospital, Linkoeping, University Hospital, Umeå, Uppsala University Hospital |
Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | First intervention free survival (FIFS) at 2 years | Survival | 2 years | |
Secondary | Total fatigue score assessed by the fatigue questionnaire developed by T. Chalder et al. | Symptom | 2, 5, 10 and 15 years | |
Secondary | Change in cognitive functioning (composite score from CANTAB-tests) at 2 years | Objective examination | 5 months and 2, 5, 10 and 15 years | |
Secondary | Overall survival | Survival | Median and at 2, 5, 10 and 15 years | |
Secondary | FIFS | Survival | Median, 5, 10 and 15 years | |
Secondary | Progression-free survival | Survival | Median and at 2, 5, 10 and 15 years | |
Secondary | Change in neurological function as assessed by the NANO scale | Objective examination | 2, 5, 10 and 15 years | |
Secondary | Global cognitive impairment index | Neuropsychological endpoint | 2, 5, 10 and 15 years | |
Secondary | Rate of local, distant and combined recurrences | Disease development | 2, 5, 10 and 15 years | |
Secondary | Rate of patients without epileptic seizures | Symptom | 5 months and 2, 5, 10 and 15 years | |
Secondary | EORTC QLQ C30-based algorithm score | Quality of life | 2, 5, 10 and 15 years | |
Secondary | Incremental cost effectiveness ratio | Health economics | 2, 5, 10 and 15 years | |
Secondary | Rate of adverse events | Toxicity | At 6 weeks, 3 and 5 months and 1 year, 2 , 5, 10 and 15 years | |
Secondary | Costs in Norwegian kroner related to loss of production caused by disease and treatment | Health economics | 2, 5, 10 and 15 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02764151 -
First in Patient Study for PF-06840003 in Malignant Gliomas
|
Phase 1 | |
Recruiting |
NCT04843085 -
Proteomic Characterization of Aggressive Oligodendrogliomas
|
||
Completed |
NCT02903784 -
Neural Basis of Language Processing
|
N/A | |
Completed |
NCT00165360 -
Prolonged Daily Temozolomide for Low-Grade Glioma
|
Phase 2 | |
Recruiting |
NCT04541082 -
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
|
Phase 1 | |
Completed |
NCT02530320 -
Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved
|
Phase 2 | |
Terminated |
NCT00389090 -
A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma
|
Phase 2 | |
Active, not recruiting |
NCT02549833 -
Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma
|
Phase 1 | |
Recruiting |
NCT06038760 -
Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)
|
||
Recruiting |
NCT05624736 -
Hierarchical Diagnosis for Adult Diffuse Glioma Based on Deep Learning
|
||
Recruiting |
NCT05345002 -
All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma
|
Phase 2 | |
Completed |
NCT03900689 -
Social Determinants of Health in Glioblastoma Population
|
||
Completed |
NCT02747407 -
Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors
|
||
Recruiting |
NCT04970615 -
Educating Brain Tumor Patients Using Patient-specific Actual-size Three-dimensional Printed Models
|
||
Recruiting |
NCT03896958 -
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
|
||
Terminated |
NCT01836549 -
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
|
Phase 2 | |
Recruiting |
NCT03796273 -
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases
|
Early Phase 1 | |
Terminated |
NCT00031538 -
Genetic Analysis of Brain Tumors
|
||
Completed |
NCT01609790 -
Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors
|
Phase 2 | |
Not yet recruiting |
NCT05513859 -
Investigational Imaging Technique During Brain Surgery
|
N/A |